이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Y-6 Sublingual Tablets for Acute Penetrating Artery Infarction (CORAL)

2026년 7월 22일 업데이트: Neurodawn Pharmaceutical Co., Ltd.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II/III Clinical Trial of Y-6 Sublingual Tablets for the Treatment of Acute Perforator Artery Territory Infarction

The goal of this clinical trial is to learn if Y-6 sublingual tablets work to improve functional outcomes in patients with acute perforating artery infarction. It will also learn about the safety of Y-6 sublingual tablets.

The main questions it aims to answer are:

Does Y-6 sublingual tablets increase the proportion of participants who achieve a modified Rankin Scale (mRS) score of 0-1 at Day 90 after treatment? What medical problems do participants have when taking Y-6 sublingual tablets?

Researchers will compare different doses of Y-6 sublingual tablets and placebo to evaluate the effectiveness and safety of Y-6 sublingual tablets in patients with acute perforating artery infarction.

Participants will:

Take Y-6 sublingual tablets or placebo according to the assigned treatment regimen.

Visit the clinic for assessments of neurological function, functional outcomes, and safety during the study period.

Complete clinical assessments, including neurological examinations, laboratory tests, and other safety evaluations.

Be followed for functional outcomes and safety events after treatment.

연구 개요

상태

아직 모집하지 않음

상세 설명

This is a multicenter, randomized, double-blind, placebo-controlled, seamless adaptive Phase II/III clinical trial to evaluate the efficacy and safety of Y-6 sublingual tablets in patients with acute perforating artery infarction. The study consists of two stages. In Stage 1, participants will be randomly assigned to receive high-dose Y-6 sublingual tablets (2 tablets, containing a total of 12 mg of borneol and 50 mg of cilostazol), low-dose Y-6 sublingual tablets (1 tablet containing 6 mg of borneol and 25 mg of cilostazol plus 1 matching placebo tablet), or placebo (2 matching placebo tablets), in addition to standard antiplatelet therapy with aspirin (100mg). The purpose of Stage 1 is to evaluate the efficacy and safety of different doses of Y-6 sublingual tablets and select the recommended dose for Stage 2 based on interim analyses reviewed by an independent data monitoring committee (IDMC). In Stage 2, participants will be randomly assigned to receive the selected dose of Y-6 sublingual tablets or placebo, in addition to concomitant aspirin therapy, to confirm the efficacy and safety of Y-6 sublingual tablets. Participants will receive study treatment and be followed for efficacy and safety outcomes, including functional outcomes, adverse events, bleeding events, and other safety assessments

연구 유형

중재적

등록 (추정된)

944

단계

  • 2 단계
  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Beijing Municipality
      • Beijing, Beijing Municipality, 중국, 100070
        • Beijing Tiantan Hospital
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

  1. Male or female participants aged ≥18 and ≤80 years;
  2. Onset of stroke within 72 hours before the first administration of study treatment;
  3. Clinical symptoms and signs suggestive of an acute isolated perforating artery territory infarction (no cortical involvement, no multifocal involvement, NIHSS score between 4 and 15, and level of consciousness item 1a ≤1);
  4. Pre-stroke modified Rankin Scale (mRS) score ≤1 before the current stroke onset;
  5. Brain magnetic resonance imaging (MRI) diffusion-weighted imaging (DWI) showing an isolated infarction lesion in the perforating artery territory (including the basal ganglia, internal capsule, thalamus, pons, etc.) with a diameter <30 mm, and meeting at least one of the following criteria:

    1. The infarct lesion involves at least 3 DWI axial slices;
    2. The maximum diameter of the lesion on DWI is ≥15 mm;
    3. The DWI lesion is connected to the ventral surface of the pons, located near the midline, unilateral, and does not cross the midline;
  6. No severe stenosis of the parent artery supplying the infarct territory (severe stenosis defined as >70% stenosis on magnetic resonance angiography [MRA], or >50% stenosis on computed tomography angiography [CTA] or digital subtraction angiography [DSA]);
  7. The participant or legally authorized representative voluntarily signs the informed consent form approved by the ethics committee.

Exclusion Criteria:

  1. Known allergy to any component of the investigational product or its excipients;
  2. Ischemic stroke caused by large artery atherosclerosis, cardioembolism, arterial dissection, or vasculitis identified at screening;
  3. History of intracranial hemorrhagic diseases within 3 months prior to screening, including intracerebral hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural hematoma, or epidural hematoma;
  4. History of other active or major neurological diseases, including recurrent seizures, intracranial tumors, vascular malformations (including arteriovenous malformations, arterial malformations, cavernous malformations), untreated aneurysms >3 mm in diameter, etc.;
  5. History of congestive heart failure, or acute myocardial infarction within 3 months prior to screening, or severe cardiac dysfunction (NYHA class III-IV);
  6. Significant head trauma, intracranial or spinal surgery, or severe physical trauma within 4 weeks prior to screening; major surgery within 3 months prior to screening; or planned endovascular treatment during the study period;
  7. Severe hepatic or renal dysfunction at screening, or meeting any of the following criteria:

    1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 × upper limit of normal (ULN);
    2. Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m² (calculated using the CKD-EPI equation based on serum creatinine; see Appendix 4);
  8. Coagulation disorders, bleeding tendency, or active systemic bleeding at screening, including but not limited to:

    1. Prothrombin time >1.5 × ULN;
    2. Platelet count <100 × 10⁹/L;
    3. Hemophilia, capillary fragility disorders, gastrointestinal bleeding, urinary tract bleeding, hemoptysis, vitreous hemorrhage, etc.;
  9. Persistent systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg despite antihypertensive treatment;
  10. Known acute gastrointestinal ulcer;
  11. History of asthma induced by salicylates or salicylate-containing substances (especially non-steroidal anti-inflammatory drugs [NSAIDs]);
  12. Continuous use of dual antiplatelet therapy within 5 days prior to screening, or administration of loading doses of clopidogrel (300 mg) or ticagrelor (180 mg) after current stroke onset and before screening, or use of antiplatelet agents other than aspirin, cilostazol, clopidogrel, or ticagrelor after current stroke onset and before screening;
  13. Received intravenous thrombolysis, thrombectomy, other endovascular treatment, or bridging therapy after current stroke onset; or received anticoagulants, batroxobin, defibrase, snake venom-derived preparations, or lumbrokinase therapy;
  14. Presence of a clear indication for anticoagulation (suspected cardioembolic stroke, such as atrial fibrillation, known prosthetic heart valve, atrial myxoma, endocarditis, etc.) or a clear indication for dual antiplatelet therapy (such as recent coronary artery stenting or intracranial artery stenting);
  15. Expected need for long-term use of NSAIDs other than the study medication;
  16. Life expectancy ≤12 months;
  17. Participation in any other interventional clinical trial within 3 months prior to screening or current participation in another clinical trial;
  18. Male participants (or their partners) or female participants who plan to conceive during the study period, or participants unwilling to use one or more non-drug contraceptive methods (such as complete abstinence, condoms, sterilization, etc.) throughout the study period;
  19. Pregnant or breastfeeding women;
  20. Any other condition considered by the investigator to potentially affect compliance or make the participant unsuitable for participation in this study.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Y-6 tablet
twice daily for 90 consecutive days
Y-6 sublingual tablets (in accordance with the optimal dose established in stage 1) taken sublingually twice daily for 90 consecutive days.
위약 비교기: Placebo
twice daily for 90 consecutive days
Placebo (in accordance with the optimal dose established in stage 1) taken sublingually twice daily for 90 consecutive days.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Proportion of participants achieving a modified Rankin Scale (mRS) score ≤1 after treatment
기간: Day 90(+7 days)
The scale ranges from 0 to 6, where a score of 0 indicates no symptoms and a score of 6 indicates death. Higher mRS scores represent greater disability.
Day 90(+7 days)

2차 결과 측정

결과 측정
측정값 설명
기간
Distribution of mRS scores after treatment
기간: Day 90(+7 days)
The scale ranges from 0 to 6, where a score of 0 indicates no symptoms and a score of 6 indicates death. Higher mRS scores represent greater disability.
Day 90(+7 days)
Proportion of participants with stroke-related disability after treatment
기간: Day90 (+7 days)
Stroke disability is defined as disability (modified Rankin Scale [mRS] score of 3-5), major adverse cardiovascular events (MACE), including myocardial infarction, stroke, and vascular death, and all-cause mortality.
Day90 (+7 days)
Change from baseline in NIHSS (National Institutes of Health Stroke Scale) scores at each assessment time point
기간: Day90 (+7 days)
The NIHSS total score ranges from 0 to 42, with higher scores indicating worse neurological outcomes.
Day90 (+7 days)
Proportion of participants achieving a Barthel Index score ≥95 after treatment
기간: Day 90 (+7 days)
The Barthel Index (BI) is a measure of activities of daily living, with scores ranging from 0 to 100. Higher scores indicate greater independence, while lower scores indicate greater dependence on assistance for daily activities.
Day 90 (+7 days)
Proportion of participants with early neurological deterioration after treatment
기간: 72 hours (±12 hours) after treatment、Day 7 (±1 day)
Early neurological deterioration means within 7 days after stroke attack, an increase in NIHSS of ≥2 points or an increase in hemiparesis of ≥1 point or an increase in impaired consciousness of ≥1 point from baseline and excluding progression of disease due to intracranial hemorrhage by examination of cranial CT or MRI and exacerbation of disease due to other non-stroke causes, such as cardiac insufficiency, hepatic insufficiency, renal insufficiency, etc.
72 hours (±12 hours) after treatment、Day 7 (±1 day)
Proportion of participants with ischemic stroke after treatment
기간: Day90 (+7 days)
Day90 (+7 days)
Incidence of moderate and severe bleeding events after treatment
기간: Day 30 (±3 days)、Day 90 (+7 days)
Bleeding events will be classified according to the GUSTO bleeding criteria. Severe or life-threatening bleeding is defined as intracerebral hemorrhage or bleeding resulting in substantial hemodynamic compromise requiring treatment. Moderate bleeding is defined as bleeding requiring blood transfusion. Minor bleeding is defined as other bleeding events not requiring transfusion or causing hemodynamic compromise.
Day 30 (±3 days)、Day 90 (+7 days)
Incidence of intracranial hemorrhage after treatment
기간: Day 30 (±3 days)、Day 90 (+7 days)
Day 30 (±3 days)、Day 90 (+7 days)
Incidence of any bleeding events after treatment
기간: Day 30 (±3 days)、Day 90 (+7 days)
Day 30 (±3 days)、Day 90 (+7 days)
All-cause Mortality after treatment
기간: Day 30 (±3 days)、Day 90 (+7 days)
Day 30 (±3 days)、Day 90 (+7 days)
Incidence of platelet count ≤100 × 10⁹/L after treatment
기간: Day 30 (±3 days)、Day 90(+7 days)
Day 30 (±3 days)、Day 90(+7 days)
Incidence of new-onset moderate-to-severe headache after treatment
기간: Day 30 (±3 days)、Day 90 (+7 days)
Headache severity will be assessed using the 11-point Numerical Rating Scale (11-NRS). The scale ranging from 0 to 10, where 0 indicates no headache and 10 indicates the worst imaginable headache. Higher scores indicate greater headache severity.
Day 30 (±3 days)、Day 90 (+7 days)
Incidence and severity of adverse events after treatment
기간: Day 90 (+7days)
Day 90 (+7days)
The Incidence of subject getting abnormal results of physical examinations after treatment
기간: Day 90 (+7days)
Day 90 (+7days)
The Incidence of subject getting abnormal results of vital signs after treatment
기간: Day 90 (+7days)
Day 90 (+7days)
The Incidence of subject getting abnormal results of laboratory tests after treatment
기간: Day 90 (+7days)
Day 90 (+7days)
The Incidence of subject getting abnormal results of 12-lead electrocardiograms after treatment
기간: Day 90 (+7 days)
Day 90 (+7 days)

기타 결과 측정

결과 측정
측정값 설명
기간
Distribution of mRS scores after treatment
기간: Day 180 (±10 days)、Day 360 (±15 days)
The scale ranges from 0 to 6, where a score of 0 indicates no symptoms and a score of 6 indicates death. Higher mRS scores represent greater disability.
Day 180 (±10 days)、Day 360 (±15 days)
Proportion of participants with stroke-related disability after treatment
기간: Day 180 (±10 days)、Day 360 (±15 days)
Stroke disability is defined as disability (modified Rankin Scale [mRS] score of 3-5), major adverse cardiovascular events (MACE), including myocardial infarction, stroke, and vascular death, and all-cause mortality.
Day 180 (±10 days)、Day 360 (±15 days)
Proportion of participants achieving a Barthel Index score ≥95 after treatment
기간: Day 180 (±10 days)、Day 360 (±15 days)
The Barthel Index (BI) is a measure of activities of daily living, with scores ranging from 0 to 100. Higher scores indicate greater independence, while lower scores indicate greater dependence on assistance for daily activities.
Day 180 (±10 days)、Day 360 (±15 days)
Proportion of participants with ischemic stroke after treatment
기간: Day 180 (±10 days)、Day 360 (±15 days)
Day 180 (±10 days)、Day 360 (±15 days)
Change from baseline in structural brain imaging parameters assessed by 3D-T1-weighted MRI
기간: Day 90(+7 days)
Day 90(+7 days)
Change from baseline in diffusion tensor imaging (DTI) parameters
기간: Day 90(+7 days)
Day 90(+7 days)
Change from baseline in functional MRI parameters assessed by BOLD-fMRI
기간: Day 90(+7 days)
Day 90(+7 days)
Change from baseline in cerebral hemodynamic parameters
기간: Day 180 (±10 days)、Day 360 (±15 days)
Day 180 (±10 days)、Day 360 (±15 days)
Changes from baseline in blood biomarker phosphodiesterase 3A (PDE3A) levels
기간: Day 90(+7 days)
Day 90(+7 days)
Change from baseline in Montreal Cognitive Assessment (MoCA) score
기간: Day 180 (±10 days) 、Day 360 (±15 days)
Day 180 (±10 days) 、Day 360 (±15 days)
Change from baseline in Digit Span Test performance
기간: Day 180 (±10 days) 、Day 360 (±15 days)
Day 180 (±10 days) 、Day 360 (±15 days)
Change from baseline in Rey Auditory Verbal Learning Test (RAVLT) performance
기간: Day 180 (±10 days) 、Day 360 (±15 days)
Day 180 (±10 days) 、Day 360 (±15 days)
Change from baseline in Color Trail Test performance
기간: Day 180 (±10 days)、Day 360 (±15 days)
Day 180 (±10 days)、Day 360 (±15 days)
Change from baseline in Stroop Color-Word Test performance
기간: Day 180 (±10 days)、Day 360 (±15 days)
Day 180 (±10 days)、Day 360 (±15 days)
Change from baseline in Functional Activities Questionnaire (FAQ) score
기간: Day 180 (±10 days) 、Day 360 (±15 days)
Day 180 (±10 days) 、Day 360 (±15 days)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 8월 31일

기본 완료 (추정된)

2028년 2월 28일

연구 완료 (추정된)

2028년 7월 31일

연구 등록 날짜

최초 제출

2026년 7월 10일

QC 기준을 충족하는 최초 제출

2026년 7월 22일

처음 게시됨 (실제)

2026년 7월 23일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 7월 23일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 7월 22일

마지막으로 확인됨

2026년 7월 1일

추가 정보

이 연구와 관련된 용어

키워드

기타 연구 ID 번호

  • Y-6-LC-05

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다